222 related articles for article (PubMed ID: 18830918)
1. Retrovirus-induced oncogenesis and safety of retroviral vectors.
Nair V
Curr Opin Mol Ther; 2008 Oct; 10(5):431-8. PubMed ID: 18830918
[TBL] [Abstract][Full Text] [Related]
2. Retroviral vectors: post entry events and genomic alterations.
Nowrouzi A; Glimm H; von Kalle C; Schmidt M
Viruses; 2011 May; 3(5):429-55. PubMed ID: 21994741
[TBL] [Abstract][Full Text] [Related]
3. Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?
Staal FJ; Pike-Overzet K; Ng YY; van Dongen JJ
Leukemia; 2008 Oct; 22(10):1849-52. PubMed ID: 18769449
[TBL] [Abstract][Full Text] [Related]
4. Genotoxicity of retroviral hematopoietic stem cell gene therapy.
Trobridge GD
Expert Opin Biol Ther; 2011 May; 11(5):581-93. PubMed ID: 21375467
[TBL] [Abstract][Full Text] [Related]
5. Novel principles of gamma-retroviral insertional transcription activation in murine leukemia virus-induced end-stage tumors.
Sokol M; Wabl M; Ruiz IR; Pedersen FS
Retrovirology; 2014 May; 11():36. PubMed ID: 24886479
[TBL] [Abstract][Full Text] [Related]
6. Insertional oncogenesis by non-acute retroviruses: implications for gene therapy.
Fan H; Johnson C
Viruses; 2011 Apr; 3(4):398-422. PubMed ID: 21994739
[TBL] [Abstract][Full Text] [Related]
7. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.
Davé UP; Akagi K; Tripathi R; Cleveland SM; Thompson MA; Yi M; Stephens R; Downing JR; Jenkins NA; Copeland NG
PLoS Genet; 2009 May; 5(5):e1000491. PubMed ID: 19461887
[TBL] [Abstract][Full Text] [Related]
8. Retroviral Insertional Mutagenesis in Humans: Evidence for Four Genetic Mechanisms Promoting Expansion of Cell Clones.
Bushman FD
Mol Ther; 2020 Feb; 28(2):352-356. PubMed ID: 31951833
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial.
Wang GP; Berry CC; Malani N; Leboulch P; Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Bushman FD
Blood; 2010 Jun; 115(22):4356-66. PubMed ID: 20228274
[TBL] [Abstract][Full Text] [Related]
10. Retroviral gene therapy: safety issues and possible solutions.
Yi Y; Hahm SH; Lee KH
Curr Gene Ther; 2005 Feb; 5(1):25-35. PubMed ID: 15638709
[TBL] [Abstract][Full Text] [Related]
11. Insertional mutagenesis by retroviral vectors: current concepts and methods of analysis.
Knight S; Collins M; Takeuchi Y
Curr Gene Ther; 2013 Jun; 13(3):211-27. PubMed ID: 23590635
[TBL] [Abstract][Full Text] [Related]
12. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
Ginn SL; Liao SH; Dane AP; Hu M; Hyman J; Finnie JW; Zheng M; Cavazzana-Calvo M; Alexander SI; Thrasher AJ; Alexander IE
Mol Ther; 2010 May; 18(5):965-76. PubMed ID: 20354504
[TBL] [Abstract][Full Text] [Related]
13. [Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials].
Doi K; Takeuchi Y
Uirusu; 2015; 65(1):27-36. PubMed ID: 26923955
[TBL] [Abstract][Full Text] [Related]
14. Biosafety considerations using gamma-retroviral vectors in gene therapy.
Deichmann A; Schmidt M
Curr Gene Ther; 2013 Dec; 13(6):469-77. PubMed ID: 24195605
[TBL] [Abstract][Full Text] [Related]
15. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.
Deichmann A; Hacein-Bey-Abina S; Schmidt M; Garrigue A; Brugman MH; Hu J; Glimm H; Gyapay G; Prum B; Fraser CC; Fischer N; Schwarzwaelder K; Siegler ML; de Ridder D; Pike-Overzet K; Howe SJ; Thrasher AJ; Wagemaker G; Abel U; Staal FJ; Delabesse E; Villeval JL; Aronow B; Hue C; Prinz C; Wissler M; Klanke C; Weissenbach J; Alexander I; Fischer A; von Kalle C; Cavazzana-Calvo M
J Clin Invest; 2007 Aug; 117(8):2225-32. PubMed ID: 17671652
[TBL] [Abstract][Full Text] [Related]
16. Trial watch: Self-inactivating gene-therapy vector alleviates safety concerns.
Cully M
Nat Rev Drug Discov; 2014 Dec; 13(12):879. PubMed ID: 25394873
[No Abstract] [Full Text] [Related]
17. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.
Sinn PL; Sauter SL; McCray PB
Gene Ther; 2005 Jul; 12(14):1089-98. PubMed ID: 16003340
[TBL] [Abstract][Full Text] [Related]
18. Reducing the genotoxic potential of retroviral vectors.
Ramezani A; Hawley TS; Hawley RG
Methods Mol Biol; 2008; 434():183-203. PubMed ID: 18470646
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy for severe combined immunodeficiencies and beyond.
Fischer A; Hacein-Bey-Abina S
J Exp Med; 2020 Jan; 217(2):. PubMed ID: 31826240
[TBL] [Abstract][Full Text] [Related]
20. Integrome signatures of lentiviral gene therapy for SCID-X1 patients.
Yan KK; Condori J; Ma Z; Metais JY; Ju B; Ding L; Dhungana Y; Palmer LE; Langfitt DM; Ferrara F; Throm R; Shi H; Risch I; Bhatara S; Shaner B; Lockey TD; Talleur AC; Easton J; Meagher MM; Puck JM; Cowan MJ; Zhou S; Mamcarz E; Gottschalk S; Yu J
Sci Adv; 2023 Oct; 9(40):eadg9959. PubMed ID: 37801507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
